MaxCyte (MXCT) Q3 2026 earnings review
MaxCyte sales rebound, and its Akron buyout uses most cash
MaxCyte, which sells tools that edit cells for medicine, returned to growth and agreed to buy chemical supplier Akron Bio. Third-quarter revenue rose 49% from a year ago to $10 million as equipment sales and Casgevy drug royalties jumped, while cost cuts halved the net loss. Chief executive Maher Masoud raised the full-year revenue outlook, which by our math leaves about 4% growth for the fourth quarter.
| Total revenue | $10.2M +49% from a year ago |
|---|---|
| Core business revenue | $8.2M +27% from a year ago |
| Full-year revenue outlook | Raised $3.5M to at least $34.5M (+5% vs 2025) |
| Year-end cash outlook (post-Akron) | $40–45M $133M without the acquisition |
⚖️ Verdict: 🟢 Bullish
The story got better because core equipment demand rebounded alongside a deal that doubles the revenue base and brings $7 million to $8 million in annual profit before interest, taxes, depreciation and amortization. Buying Akron cuts top-customer reliance in half and opens viral cell therapies to the sales team. The bad news: paying $105 million in cash, issuing 20% more shares, and borrowing $22 million takes away the debt-free cash cushion.
The question now is whether the combined business can reach positive cash flow before it needs more of its new loan. Either Akron's reagent profits and rising Casgevy royalties cover the remaining cash use, or slow cell-therapy funding forces deeper borrowing. Next year's combined cash burn against the $10 million target will tell.
🐂 Bull Case
Akron Bio Deal Doubles Revenue Base
MaxCyte builds instruments that use electrical pulses to insert genes into cells. Chief executive Maher Masoud announced a $151.8 million agreement to buy Akron Bio, calling it "a transformational moment for MaxCyte." Akron supplies chemical liquids and proteins used to grow and freeze cells before and after gene editing, "expanding our presence across the viral and non-viral cell therapy development and manufacturing workflow," Masoud said.
- Akron 2026 expected revenue: about $28 million, with $7 million to $8 million in EBITDA (earnings before interest, taxes, depreciation and amortization)
- Commercial and late-stage drug programs supported: triples from 4 to 12, including 5 approved therapies
- Top customer share of projected 2026 revenue: drops from 27% for MaxCyte alone to 14% combined
This deal addresses a standing risk that MaxCyte relied too heavily on non-viral editing and a single large partner, Vertex. Because only about 10% of customers overlap today, MaxCyte can sell Akron's liquids to its own instrument users and cut its expected 2027 cash use below $10 million.
What to watch: the closing of the Akron acquisition before the end of 2026 and the first combined 2027 revenue outlook. That plan will show whether Akron achieves the low-to-mid-teens growth rate management projected in its presentation.
Core Equipment and Consumable Sales Rebounded
MaxCyte's core business sells and leases cell-engineering instruments and single-use processing assemblies (PAs), the sterile plastic cartridges used in each run. After shrinking by more than a fifth in both the first and second quarters, core revenue rose 27.3% from a year ago to $8.2 million in the third quarter, "exceeding the growth expectations we established at the beginning of 2026," Masoud said.
Instrument sales doubled to $2.8 million, PA sales grew 20.0% to $3.1 million, and license fees rose 9.1% to $2.0 million. The company signed a multi-platform license with Genentech in July, and Masoud noted that "Our enterprise pharma partnership is off to a strong start." While last year's third quarter was an easy comparison, total core sales also climbed 25.4% from the second quarter.
What to watch: fourth-quarter core revenue against the $7.1 million implied by the full-year outlook, by our math. Hitting or beating that mark will confirm that per-instrument cartridge usage has stabilized after a year of declines.
Casgevy Royalties Beat the Second-Half Plan
Under its Strategic Platform License (SPL) agreements, MaxCyte collects development milestones and commercial royalties when drug partners advance and sell cell therapies. Third-quarter SPL revenue nearly quintupled from a year ago to $2.0 million, split evenly between $1.0 million in clinical milestones and $1.0 million in royalties from Vertex's Casgevy therapy.
Three months ago, the full-year outlook called for $2.0 million in royalties, which left $0.81 million for the entire second half by our math. Third-quarter royalties of $0.99 million beat that six-month remainder in a single quarter. Management raised its full-year SPL target to at least $6.5 million, including at least $2.5 million in royalties.
What to watch: fourth-quarter royalty revenue against the $0.32 million floor implied by the new outlook, by our math. Another reading near $1 million would show the raised target is still cautious.
Cost Cuts Halved the Quarterly Loss
MaxCyte cut its workforce by a third in September 2025 to lower its cash use. In the third quarter, total operating expenses fell 25.1% from a year ago to $14.5 million, or 11.1% by our math when excluding last year's $3.1 million restructuring charge. Every major cost line shrank as a share of sales: research and development fell 49.5 percentage points to 28.3% of revenue, general and administrative overhead dropped 23.7 percentage points to 64.5%, and sales and marketing fell 16.1 percentage points to 41.5%.
Higher high-margin licensing and SPL revenue also lifted GAAP gross margin by 6.8 percentage points to 83.4%, cutting the quarterly net loss from $12.4 million to $4.8 million. What to watch: fourth-quarter operating expenses, to see how much deal and legal cost from the Akron acquisition hits the income statement before year-end.
🐻 Bear Case
Akron Deal Takes Most of the Cash Pile
Before the Akron deal, MaxCyte held $132.7 million in cash and investments and carried no debt, giving investors a large cash cushion while the business lost money. Buying Akron requires $105.0 million in upfront cash, 20.6 million new MaxCyte shares valued at $26.8 million, and $20.0 million in guaranteed deferred payments due in January 2028 and January 2029.
To keep a working buffer, the cell-engineering company will draw $22.0 million at closing from a new $75.0 million credit facility with MidCap Financial. That leaves $40.0 million to $45.0 million in year-end cash against $42.0 million in debt and deferred obligations, while existing stockholders face 20.0% share dilution by our math. Management expects the deal to "reduce the combined company’s annual cash burn to less than $10 million in 2027" and "reach profitability without fully utilizing its credit facility."
What to watch: the interest rate and financial covenants on the MidCap loan in the quarterly filing. Those terms will determine how much interest cash MaxCyte loses while moving from net interest income to net debt.
Assay Services Shrank as One Partner Exited
Masoud highlighted pipeline progress, noting SPL partners have "more late-stage programs than ever before, including two pivotal trials that could result in approvals as early as next year." While clinical-stage SPL programs rose from 12 to 13, total SPL agreements fell from 29 to 28 as partner attrition continued.
Meanwhile, SeQure Dx — MaxCyte's assay service that tests gene-edited cells for unintended DNA changes — saw revenue fall 82.7% from a year ago and 82.4% from the second quarter to $43 thousand. That drop cuts against management's claim of broad momentum across every stage from discovery to commercialization.
What to watch: fourth-quarter assay service revenue and the active SPL partner count. Another quarter near zero for assay services would confirm that safety testing is not becoming a meaningful revenue stream.
Risks this quarter didn't answer
Three standing watch items from prior quarters could not be read from the earnings release and presentations.
- Installed instrument base: not in the release after reaching 899 in Q2; the quarterly filing will show whether placements kept growing.
- Genentech enterprise terms: management did not disclose upfront fees or whether the deal trades away future commercial royalties.
- Internal milestone forecast: the release gave no update on the lowered milestone assumptions that triggered an asset test in the first half.
💲 Other KPIs
Current deferred revenue — cash billed to customers for annual instrument licenses and multi-platform access not yet recognized as sales — tripled from $2.46 million in the second quarter to $7.39 million. That jump reverses three quarters of decline and follows the July signing of the Genentech enterprise agreement.
Uncollected customer bills rose 244.1% from $3.50 million at the end of 2025 to $12.05 million, absorbing $8.55 million of operating cash over the first nine months. The surge matches the jump in deferred revenue and third-quarter milestone and royalty billings, meaning cash collection lagged revenue and contract signings.
Average shares fell 2.9% from a year ago and 3.1% from the second quarter after the group spent $5.5 million to buy back 4.26 million shares. That reduction will reverse when the Akron deal closes and adds 20.6 million new shares.
🔮 Guidance
Raised. Management lifted the full-year floor by $3.5 million above the middle of its prior range, pointing to at least 4.7% growth over 2025's preliminary total by our math. After $27.1 million in the first nine months, that floor leaves at least $7.4 million for the fourth quarter, up about 3.9% from a year ago.
Raised. The new target sits $2.0 million above the middle of the prior range, though it still represents a 5.2% decline for the full year by our math. It leaves about $7.1 million of core revenue for the fourth quarter, up 7.1% from a year ago, matching management's statement of roughly 15% core growth across the second half.
Raised. The outlook moved up by at least $1.5 million, comprising about $4.0 million in milestones (already reached in the first nine months) and at least $2.5 million in royalties (up from $2.0 million). By our math, that leaves at least $0.30 million in fourth-quarter SPL revenue, down 39.4% from a year ago because no fourth-quarter milestones are included.
Raised. Excluding the Akron purchase price and deal costs, the year-end cash target moved up $2.5 million from the prior floor. Because third-quarter cash already stood at $132.7 million, the standalone business expects positive cash flow in the fourth quarter as customers pay down the $12.1 million receivables balance.
New. Assuming the Akron acquisition closes before year-end, the company expects to finish 2026 with $40.0 million to $45.0 million in cash and investments. That figure accounts for $105.0 million in upfront cash and deal costs, offset by $22.0 million borrowed under the new MidCap credit facility.
❓ Key Questions
What are the interest rate and covenants on MidCap debt?
MaxCyte is drawing $22 million at closing from a $75 million facility while shifting from $133 million in cash to $40–45 million. The interest rate and minimum revenue or liquidity covenants will determine its true cash runway.
How much of the $7.4M deferred revenue is from Genentech?
Current deferred revenue tripled to $7.39 million in the quarter Genentech signed, while accounts receivable jumped by $8.55 million since year-end. Investors need to know the annual license rate and whether the contract includes commercial royalties.
Why did SeQure assay revenue drop to $43 thousand?
Assay services fell 83% from both last year and last quarter to $43 thousand, even after the company integrated SeQure Dx to expand its market. Management has not explained whether customer orders paused or pricing changed.
Which partner exited to bring SPL agreements down to 28?
Total SPL agreements fell from 29 to 28 in the third quarter even as active clinical programs rose from 12 to 13. Identifying whether a preclinical partner terminated its deal clarifies the remaining milestone pipeline.